Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Gore

Showing results (191-200 of 215) with videos related to

Pageof 22
Sort By:
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Journal of Clinical Investigation|December 7, 2023
PD-1H/VISTA mediates immune evasion in acute myeloid leukemiaTae Kon Kim, Xue Han, Qianni Hu, et al.
The Journal of Biological Chemistry|May 3, 2011
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qLi Zhou, Joanna Opalinska, Davendra Sohal, et al.
Blood Advances|February 11, 2026
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History StudyAmy E DeZern, Nancy Gillis, Michael Otterstatter, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Leukemia & Lymphoma|May 22, 2019
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromesMikkael A Sekeres, Steven D Gore, Donald M Stablein, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 22

Showing results (191-200 of 215) with videos related to

Sort By:
Pageof 22
Blood|December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideJudith E Karp, Karen Flatten, Eric J Feldman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncologyPeter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Leukemia & Lymphoma|July 3, 2018
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemiaMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
The Journal of Clinical Investigation|December 7, 2023
PD-1H/VISTA mediates immune evasion in acute myeloid leukemiaTae Kon Kim, Xue Han, Qianni Hu, et al.
The Journal of Biological Chemistry|May 3, 2011
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7qLi Zhou, Joanna Opalinska, Davendra Sohal, et al.
Blood Advances|February 11, 2026
A novel approach to defining progression in MDS and precursor myeloid conditions in The MDS Natural History StudyAmy E DeZern, Nancy Gillis, Michael Otterstatter, et al.
Cancer|March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Leukemia & Lymphoma|May 22, 2019
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromesMikkael A Sekeres, Steven D Gore, Donald M Stablein, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Pageof 22